CD40 Ligand (CD40L) as Vaccine Adjuvant
The adjuvant can non-specifically change or enhance the specific immune response of the body to the antigen, so that the body can produce a long-term, high-efficiency specific immune response, increase the body's immune response intensity, reduce the amount of immune substances, and save the production cost of the vaccine. Creative Biolabs, a leader in vaccine development in the industry, has extensive experience in the design and development of adjuvants to help customers select the optimal adjuvant.
CD40 Ligand (CD40L)
CD40 ligand (CD40L), also known as CD154, gp39, tumor necrosis factor-related activating protein (TRAP), T cell-B cell activating molecule, etc., is a member of the TNF superfamily. It is widely distributed, mainly expressed on the surface of activated T cells, especially activated CD4+ T cells. The interaction of CD40L with CD40 has a wide range of biological significance, such as mediating T cell-dependent B cell activation, proliferation and differentiation, mediating isotype switching and secretion of antibodies, and preventing B cells from apoptosis at all stages of development. In addition to its role in humoral immune responses, the interaction of CD40L with CD40 allows epithelial cells to express adhesion molecules, induce multiple cell types, express pro-inflammatory cytokines, and regulate macrophage and DC cell expression of chemokines, all of which are also extremely important for cellular immune responses. Moreover, studies also found that CD40L also plays an active role in anti-tumor immunity and tumorigenesis. CD40L can not only directly inhibit tumor cell growth, but its binding to CD40 can also up-regulate the expression of endogenous polypeptides in tumor cells and improve the immune system’s ability to present tumor antigens. Based on studies of the function of CD40L and its interaction with CD40, CD40L acts as a costimulatory molecule involved in the immune response to enhance the vaccine's effectiveness.
CD40L as Vaccine Adjuvant
The trimer formed by CD40L-CD40 ligation on the surface of antigen-presenting cells (APCs) such as B cells and DC cells can be combined with TNF receptor-related factors for signal transduction. And by activating APCs and immune cells, CD40L participates in the induction and regulation of specific humoral and cellular immune responses. These are the functional basis for their use as adjuvants.
- CD40L Adjuvant for Viral DNA Vaccine
A study in which a CD40L-encoding plasmid and a galactosidase gene-encoding plasmid were co-immunized in mice showed that the levels of anti-galactosidase antibodies produced by the mice after mixed inoculation were significantly increased, and the activity of CTL cells was also significantly enhanced. In addition, HIV DNA vaccine, influenza DNA vaccine, RSV DNA vaccine and other combined vaccination studies with CD40L have all demonstrated that CD40L can enhance the efficacy of DNA vaccines and its potential as an immunoadjuvant.
- Role of CD40L in Cancer Treatment
Earlier studies found that CD40L inhibits tumor cell growth and activates anti-tumor immunity, whereas subsequent studies have shown that CD40L is associated with tumor development. In a study, HPV16's oncogene E7 was recombined with CD40L, and mice immunized with such preparation were found to have enhanced E7-specific humoral and cellular immune responses as well as anti-tumor effects, and a large number of E7-specific CD8+ T cells were observed. An adenovirus-based vaccine expressing HPV E7 and CD40L fusion proteins was also found to have induced activated CD8+ T cells with tumor cell killing function in immunized mice, and inhibited tumor growth was also observed in mice. Moreover, CD40L can also increase the sensitivity of some tumor cells to some apoptosis-inducing agents, indicating that in addition to directly affecting the growth of tumor cells, CD40L can also enhance the apoptosis-promoting effects of other chemotherapeutic drugs.
Services for CD40L-based Vaccine Adjuvant
- Design and development of CD40L-based adjuvant
- Optimization of vaccine formulation
- Development of CD40L-antigen fusion vaccine
- Evaluation and data analysis of CD40L-adjuvated vaccine
- Other custom services related to CD40L-adjuvated vaccine
Creative Biolabs is a leader in the vaccine industry, providing one-stop vaccine design, manufacturing, formulation development and evaluation services. In the development of adjuvants, we have development experts professional in various types of adjuvants to help you choose the most suitable adjuvant and optimize your vaccine formulation.
All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.
